Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3700-0.0300 (-2.14%)
At close: 04:00PM EDT
1.4100 +0.04 (+2.92%)
After hours: 05:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.4000
Open1.4000
Bid1.3700 x 3200
Ask1.3800 x 900
Day's Range1.3600 - 1.4000
52 Week Range1.1700 - 3.6200
Volume71,418
Avg. Volume262,868
Market Cap65.788M
Beta (5Y Monthly)-0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.3950
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GNPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genprex, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    Genprex to Present at Upcoming October Investor and Industry Conferences

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.

  • PR Newswire

    Genprex to Present at Upcoming September Investor Conference

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes at the following investor conference in September 2022.

  • PR Newswire

    Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2. The patent covers methods of using REQORSATM Immunogene Therapy in conjunction with immune checkpoint inhibitors, through 2038.

Advertisement
Advertisement